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Superovulation has been a hot topic in equine reproduction for many years. Despite all the research conducted, there is still no commercially available product to be used in equine practice. The high costs, reported negative side effects [1] and the lack of a commercially available product (equine FSH is off the market) prevent the use of superovulation in private practice. 

Superovulation offers several potential benefits: an increase in embryo recovery or oocyte collection, enhancement of fertility in subfertile mares, advancement of the first ovulation of the year and producing extra embryos for freezing [1].





The mare’s ovary is considered to be “inside out”, with the cortex in the interior of the ovary and the medulla toward the periphery.  Ovulation takes place through the ovulation fossa, a small area lined with germinal epithelium. The number of ovulations may be limited by the small space available at the ovulation fossa, large follicle size and the tunica albuginea. 

Researchers have tried several different approaches to induce superovulation in mares. The administration of GnRH to transitional mares resulted in multiple ovulations. However in regular cycling mares GnRH treatment did not resulted in multiple ovulations [4]. Equine chorionic gonadotropin has been shown to have little, if any, effect in the mare to stimulate follicular development and ovulation during estrus. This is probably due to the inability of eCG to bind to ovarian tissue during estrus [5]. Secretion of inhibin from the dominant follicle suppresses FSH secretion. Active immunization of mares against inhibin resulted in doubling of the ovulation rate [6]. Adverse reactions at the injection site have prevented the commercial use of inhibin vaccines for superovulation [6]. 

Follicle stimulating hormone produced by gonadotroph cells of the anterior pituitary supports the emergence and the initial growth and development of ovarian follicles.
Equine pituitary extract (EPE) contains both LH and FSH. Levels of LH that are too high can result in a poor ovulatory response in cattle. However researchers could not find a significant difference in ovulatory response between EPE and purified EPE [3, 7, 8]. EPE is a biological extract that is not readily available, expensive and causes biosecurity risks (equine spongiform encephalopathy/viruses). Summarized over several studies performed at Colorado State University, the ovulation rate after EPE treatment ranged from 2.3-3.9 with an average of 2 embryos recovered [1]. Thus the mare is moderately responsive to EPE treatment. There is, however, an extreme variation between mares in response to an EPE treatment. Based on several studies eFSH resulted in a similar ovulatory response as EPE [1]. Equine FSH was commercially available in the USA

Recombinant equine FSH could potentially induce superovulation in mares. Recombinant FSH is a single chain structure produced in a laboratory. Recombinant proteins will yield gonadotropins of a more homogenous composition that can be standardized with respect to mass and bioactivity. It could then be easier to determine the dose of recombinant FSH needed to induce superovulation. 





Most mares experience one follicular wave (70%) and thus it is important to initiate treatment at the beginning of the follicular wave prior to the emergence of a dominant follicle [13]. If mares have two follicular waves, treatment may be initiated when follicles from the first wave are becoming atretic and others from the second wave are in the growth phase. The dominant follicle secretes inhibin and estrogen which suppresses FSH levels. When FSH levels decline, the smaller follicles become atretic and only the dominant follicle will ovulate. The exogenous FSH treatment should start before follicles reaches 25 mm in size [13].  Starting FSH therapy when a single follicle is larger then 30 mm only results in one ovulation [14]. The best time to initiate FSH treatment is approximately 5-7 days after ovulation, around the time of emergence of the first follicular wave.

The current protocol used to induce superovulation [13] starts ultrasounding the mare 5-7 days after ovulation. Once the largest follicle is 22 to 25 mm in diameter, equine FSH treatment starts. The eFSH is administered intramuscularly twice daily at a dose of 12.5 mg. Prostaglandins are administered on the second day of treatment. Once most of the follicles are 32-35 mm the eFSH treatment ends; most mares require 4 or 5 days of treatment. The mare is allowed to coast for approximately 36 hours without any gonadotropin treatment and then hCG is administered. Insemination is performed according to standard procedures and the mare is flushed for embryos 7 or 8 days after ovulation.

Treatment with eFSH over consecutive cycles may result in superovulation, but the duration of therapy will be significantly longer after the first cycle [14]. However Squires reported no significant difference in ovulatory response in repeated eFSH treated mares compared with every-other-cycle treated mares [13]. To induce ovulation in mares treated with FSH it is possible to use hCG or deslorelin (GnRH agonist).  
However, administration of hCG was significantly more effective in stimulating the ovulatory response than the use of a GnRH agonist [13]. There is no advantage of pre-treating mares with progesterone and estradiol prior to the onset of eFSH therapy [14].









The aim of the current study was to compare the superovulatory response in mares treated with porcine FSH and recombinant equine FSH and to evaluate the frequency of FSH administration. The expectation was that recombinant equine FSH would result in a better superovulatory response because it would bind with higher affinity to receptors on the mare’s ovary. Measuring FSH pulses in the peripheral circulation every 3 minutes resulted in a total of 3 pulses per hour in estrus and 5 pulses per hour during the middle and late luteal phase in untreated mares [15]. The expectation for this research project is that the higher administration frequency would result in a better superovulatory response because it more closely mimics the pattern of endogenous FSH release.

2. Materials and methods
	
2.1 Experiment 1- Porcine FSH treatment











Group 2 mares (n=5) received 25 mg of porcine FSH (Folltropin-V, Bioniche) intramuscularly four times a day. Folltropin-V is registered for use in reproductively mature cows to induce superovulation; it is a purified gonadotropin extract obtained from porcine pituitary glands. When reconstituted, the final solution contains 20 mg/ml. Mares were examined daily by ultrasound to detect follicular size beginning 4 days post-ovulation. Treatment with porcine FSH was initiated when the diameter of the largest follicles was 18-22 mm. Mares received 250 μg of cloprostenol sodium (Estrumate) intramuscularly on the second day of porcine FSH treatment. Treatment was continued until the diameter of the largest follicle was ≥ 35 mm. Mares were allowed a 36 hour coast period and were then administered 2500 IU hCG intravenously to induce ovulation. Mares were inseminated and embryo recovery attempt performed as described for the control group. Group 3 mares (n=5) received 50 mg of porcine FSH (Folltropin-V, Bioniche) intramuscularly four times a day. The rest of the treatment protocol was the same as described for mares in group 2.  

Treatment groups 4 (n=10), 5 (n=9) and 6 (n=9) were treated with 25 mg, 50 mg and 100 mg porcine FSH twice a day respectively. The treatment protocols were the same as for the other groups  

2.2 Experiment 2- Recombinant equine FSH treatment

The porcine FSH treated mares from experiment 1 were allowed to go through an untreated estrous cycle before being randomly reassigned to one of three new treatment groups. Group 1 mares (n=5) were administered 0.25 mg recombinant equine FSH 
(Aspen Bio Pharma, Castle Rock, Co) intramuscularly four times a day. Group 2 (n=5) mares were administered 0.5 mg recombinant equine FSH intramuscularly four times a day. Group 3 mares were administered 0.5 mg twice a day. The treatment protocol matched the protocol used in Experiment 1; the only difference was the use of recombinant equine FSH instead of porcine FSH. Recombinant equine FSH is a genetically cloned single chain gonadotropin devoid of LH. The reFSH was provided by Aspen Bio Pharma (Castle Rock, Colorado) as a frozen solution containing 2.18 mg reFSH per ml. Before injection, the reFSH was thawed, filtered and diluted with bacteriostatic 0.9 % sodium chloride solution to the final 0.5 mg/ml concentration.


















Treatment Group	# Cycles	% Mares that Ovulated ***	Ovulation Rate* (mean/s.d.)	Embryo Recovery per Flush** (mean/ s.d.)	Embryo Recovery per Ovulation **
Control	17	100	1.3 ± 0.5	    0.6 ± 0.7	0.5
p-FSH 25 mg QID	5	100	1.2 ± 0.5	    0.6 ± 0.6	0.5
p-FSH 50 mg QID	5	100	1.2 ± 0.5	    0.4 ± 0.6	0.3
p-FSH 25 mg BID	10	100	1.0 ± 0.0	    0.7 ± 0.5	0.7
p-FSH 50 mg BID	9	100	1.2 ± 0.7	    1.1 ± 0.3	0.9
p-FSH 100 mg BID	9	100	1.7 ± 0.5	    0.7 ± 0.7	0.4
re-FSH 0.25 mg QID	5	80	3.0 ± 2.0          	   0.8 ± 0.8           	0.2
re-FSH 0.50 mg QID	5	80	4.0 ± 3.3	    1.8 ± 2.5	0.4
re-FSH 0.50 mg BID	8	75	0.8 ± 0.7	    0.7 ± 0.5	0.6
* Includes data from all mares treated; ** Only mares that ovulated were flushed
















Treatment Group	# Cycles	Days of treatment (mean/s.d.)         	# Follicles = 35 mm (mean/s.d.)
Control	17	-	1.3 ± 0.5
p-FSH 25 mg QID	5	4.8 ± 1.1	1.2 ± 0.5
p-FSH 50 mg QID	5	5.8 ± 0.5	1.4 ± 0.6
p-FSH 25 mg BID	10	5.8 ± 1.3	1.0 ± 0.0
p-FSH 50 mg BID	9	4.2 ± 1.6	1.2 ± 0.7
p-FSH 100 mg BID	9	5.0 ± 1.7	1.7 ± 0.5
re-FSH 0.25 mg QID	5	4.4 ± 0.5	4.0 ± 1.6
re-FSH 0.50 mg QID	5	4.8 ± 0.4	4.8 ± 2.0
re-FSH 0.50 mg BID	8	3.9 ± 1.7	1.8 ± 1.1

The porcine FSH treatment did not result in a superovulatory response in any of the treated mares. There were no significant differences between the treatment groups.  The embryo recovery and the number of pre-ovulatory follicles were not significantly different to the control group. Treatment with pFSH did not affect the number of days to the development of a pre-ovulatory follicle. The duration of the pFSH treatment was between 4.2 and 5.8 days. No negative side effects were reported during or after the pFSH treatment. The variation in dose and frequency of administration had no influence on the results.







There are four publications about the use of porcine FSH to induce superovulation in mares. There is no consistency in the results shown in these papers and each paper has a different type of conclusion. The current study was performed in cooperation with the producer of Folltropin to determine if pFSH is able to induce multiple ovulations in mares and to verify the previous research results. It is interesting to note that three papers [10, 11, 12] concluded that there was a significant response and that pFSH could be of practical value to induce superovulation in mares

Irvine (1981) tried to induce multiple ovulations using porcine FSH. During late summer 4 mares were given s.c. injections of 150 mg and 200 mg porcine FSH (Armour-Baldwin laboratories) at 8 am and 9 am on day’s 15-18 post-ovulation. The porcine FSH treatment resulted in 3.8 ± 0.8 follicles reaching the pre-ovulatory size of > 25 mm. In the control cycles of these mares only 1.0 ± 0 follicles reached the > 25 mm size. 

The mean ovulation rate for porcine FSH treated mares was 1.7 ± 0.6 compared with 1.0 ± 0 in the control cycles. Only in one of the treated mares an embryo flush was performed on day 7, resulting in one embryo. The percentage of ovulated follicles is relatively low considering the amount of > 25 mm follicles. The ovulation rate could potentially increase if the used dose of porcine FSH was lower or if hCG was administered when follicles were ≥ 35 mm.  The conclusion was that this experiment has shown that multiple > 25 mm follicles can be induced by porcine FSH. Irvine’s treatment group was too small for a decent conclusion. The treatment protocol was unconventional with two doses one hour apart for only three days. The embryo flushing results are of limited value because only one flush was performed. The fact that more follicles reached “pre-ovulatory” size suggests that mares were responding. Irvine defined 25 mm follicles as pre ovulatory although it is more likely to consider a 35 mm follicle as pre ovulatory. It is unlikely to consider a 25 mm follicle as pre ovulatory because it will not respond to ovulation inducing agents (hCG, reLH, GnRH, Ovuplant) [16]. Considering the results of the current study it is not likely that a lower pFSH dose would increase ovulation rate. The administration of hCG could potentially increase ovulation rate. 

Squires et al. (1986) compared the efficacy of equine pituitary extract versus porcine FSH for inducing multiple ovulations in mares. On day 12 of diestrus mares were given 150 mg of porcine FSH every 12 hours until at least two follicles reached =35 mm. On the first day of treatment the mares were given PGF2α. HCG was given once a 35 mm follicle was detected. The embryo flushes were performed 6 or 8 days post-ovulation. The overall ovulation rate for the porcine FSH treatment group (n=9) was 1.6 (± 0.7) compared with 1.0 (± 0.2) for the control group (n=30). The percentage of mares with multiple ovulations was 3% for the control group and 44.4% for the pFSH treated mares. The mean duration of pFSH treatment was 6.8 days per cycle. 


The increase in size of the largest follicle occurred sooner in porcine FSH treated mares than in control mares; it also increased the size of the second largest follicle (26.1 mm versus 19.5 mm in controls).  The conclusion was that it is not recommended to use porcine FSH in practice to induce multiple ovulations in mares because it is expensive and there are only minimal results. Squires’ treatment protocol matches almost completely with the protocol used in the current study. In the current study there is no significant difference in ovulation rate between treatment or control groups. The reason for the better results in Squires’ project might have been the higher pFSH dose (150 mg) used. The response to pFSH was still minimal and not relevant for use in practice.

Sirois et al. (1992) used porcine FSH (Folltropin-V) to induce superovulation in mares, starting on day 6 of the cycle. The mares were given 5 mg PGF-2α (lutalyse) on day 5 and day 6  to regress the CL. Porcine FSH was administered twice a day (every 12h) until at least one ≥40mm follicle was present. Only mares without a large growing follicle >25mm on day 5 were used. None of the mares ovulated more than two follicles in this study. When data from mares injected with 8 or 16 mg Folltropin were pooled for 1990 and 1991 the double ovulation rate was 11/17 (65%) as compared with 3/15 (20%) for saline injected controls. These results suggest that twice daily injection of 8-16 mg Folltropin early in the estrus cycle provide a useful protocol for inducing double ovulations. Sirois continued the treatment until a 40 mm follicle was present and used no coasting period or ovulation inducing agents. There are significantly more double ovulating mares in some treatment groups compared with the controls. Some of the treatment groups were too small (n=2) to be of any value. It would be more reliable if this research was conducted within the same year. These results suggest a positive reaction to the pFSH treatment.

Krekeler et al. (2006) tried to determine an effective dose of porcine FSH (Folltropin) required to increase the ovulation rate. Five mares were each treated with two different dose regimes of pFSH during consecutive cycles. Each mare underwent each treatment protocol at least twice. Untreated cycles of the same mares served as controls (n=33). On day 6 post ovulation each mare was started on twice daily IM injections of either 10 mg (n=10) or 25 mg (n=15) of porcine FSH. Treatment continued until follicles reached an average diameter of 35 mm (including all follicles >25 mm), at this time mares received 1500 IU of hCG iv. Embryo recovery flushes were performed on day 7 post last ovulation. The mean duration of pFSH treatment was 6.7 (±1.3) days per cycle. 
The reported ovulation rate for the control group was 1.1 (±0.1). The mares treated with 10 mg and 25 mg ovulated respectively 2.2 (±0.6) and 2.3 (±0.3) follicles per cycle. 
The 10 mg treatment resulted in 0.7 (±0.6) embryos per flush, the 25 mg treatment in 1.3 (±0.6) embryos per flush. The dose of pFSH had no effect on the number of ovulations per cycle but fewer embryos were recovered from mares that received the lower dose of pFSH. The conclusion was that porcine FSH offers an affordable, readily available means of significantly increasing the ovulation rate and embryo yield in embryo donor mares. 
Krekeler only used five mares and two of them were Thoroughbreds. This is a relative small treatment group compared with the current study and Thoroughbreds are known for a high percentage of double ovulations. 

The mares were treated during consecutive cycles; it would be more reliable to treat every other cycle. Even with 2.2 ovulations per cycle, it is still questionable to conclude that “porcine FSH offers an affordable, readily available means of significantly increasing the ovulation rate and embryo yield in embryo donor mares” considering the costs and efforts involved. The embryo recovery rate for the 10 mg (2.2 ovulations) group was not impressive (0.7). The pFSH treatment was continued until all ≥25 mm follicles reached 35 mm and there was no coasting period. In the current study the coasting period started when the biggest follicle reached 30-35 mm in size. This is potentially the reason for the different ovulation rate in both studies. It is certainly a reason for the longer treating period compared with the current study.





The recently developed genetically cloned recombinant equine FSH is capable of inducing superovulation in the mare. Despite the large number of pre-ovulatory follicles, several mares failed to ovulate. A significant amount of the non-ovulating follicles developed into luteinized, persistent anovulatory follicles. 

In mares, use of hormones from other species may be unsatisfactory due to their potential in eliciting an immune response. One such hormone that induces an antibody response is hCG [17]. 

Treatment with pituitary extracts or GnRH results in exposure of the ovaries to a relatively fixed ratio of LH and FSH, offering limited possibilities of manipulating the follicular development and ovulation. Equine pituitary extract (EPE) is a  purified gonadotropin preparative that contains only 8-10% LH and 6-8 % FSH, requiring the use of large treatment doses to be effective[18].
In the rat the superovulatory response to FSH can be impaired by the addition of LH; follicles either luteinized or became atretic [19]. EPE and purified eFSH contain eFSH:eLH ratios in the range of 5:1 to 10:1 [13, 20]. Surprisingly the embryo-to-ovulation ratio decreased using reFSH compared with EPE or eFSH. It appears that repetitive treatment with reFSH resulted in suppression of the LH surge [21]. This may be due to the negative feedback effects of elevated plasma oestradiol concentrations produced from the higher number of pre-ovulatory follicles present. 
LH is important for the final follicular and oocyte maturation. Oocytes require the presence of LH to stimulate granulosa and cumulus cells to secrete factors important for maturation of the oocyte and its competence for fertilization. The administration of hCG in a suppressed LH environment worked relatively well to induce ovulation but seems to have less effect on oocyte maturation. The higher inhibin concentrations may also have had a negative effect on oocyte maturation [21]. The poor embryo-to-ovulation ratio in reFSH treated mares may be a function of poor oocyte maturation due to suppressed LH and increased inhibin concentrations. 

Studies indicate that the in vitro biological activity of the single chain recombinant FSH is comparable to the corresponding native equine heterodimer [22].
Niswender et al. [23] performed two experiments to determine the in vivo activity of reFSH. The first experiment examined follicle development in mares using a follicle suppression model (progesterone and estradiol). The reFSH administration resulted in significant follicle growth during the suppression therapy. There was an increase in the number of pre-ovulatory follicles (4.4) following reFSH treatment but the ovulation rate was unchanged compared with the control group. The aim of the second experiment was to determine an effective dose of reFSH for inducing follicle growth in the normal cycling mare. The mares were randomly assigned to different treatment groups and given 0.85 mg reFSH every 12 h, 0.85 mg reFSH every 24 h and 0.5 mg reFSH every 12 h. The ovulation rate for the reFSH treated mares ranged between 3.2 and 5.4 ovulations, with no significant differences between treatment groups. The number of ≥ 35 mm follicles remaining at the time of ovulation ranged between 0.6 and 2.6. 

Roser et al. [21] administered reFSH intravenously (0.85 mg, Aspen Bio) twice a day for three days and once daily thereafter until a follicle reached ≈32 mm. The treatment started when follicles reached 20-23 mm in size. The mares (n=8) were allowed a coast period and ovulation was induced using reLH and hCG 24h apart. Daily blood samples were collected to compose a hormone profile. The reFSH treated mares had 5.5 ± 0.7 pre-ovulatory size follicles and 3.7 ± 0.7 ovulations. The number of embryos recovered was 1.7 ± 0.4; the embryo-per-ovulation recovery rate was 0.5 ± 0.11. The embryo-to-ovulation rate was similar in the reFSH treated and control group. A significant difference in circulating concentrations of LH, FSH, oestradiol and inhibin were observed between the control and reFSH group during treatment, post treatment and during the pre-ovulatory/post-ovulatory LH surge. Plasma concentrations of LH were significantly lower in reFSH treated mares compared with controls. The plasma concentration of FSH on day 5 prior to ovulation was higher in reFSH treated mares, but lower 3 to 7 days post ovulation. The plasma oestradiol and inhibin concentrations were higher for the reFSH treated mares compared with the control group. In this study the ovulation rate and embryo numbers were higher than reported for EPE or equine FSH.  

Squires et al. [13] reported that 25% of eFSH treated mares provide no embryos. In cattle, 20% of superovulated donors produce no embryos [24]. Recombinant equine FSH appears to increase the number of follicles for ovulation, but the number of ovulations and number of embryos obtained do not appear to always correlate with the number of follicles developed.
5. Conclusion
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Mare	Dose porcine FSH QID	#  follicles =35 mm	# Ovulations	# embryo’s	Days in treatment
0246	50mg	1	1	1(expanded blastocyst, 500 microns, grade 1)	6





1069	25mg	1	1	1 (expanded blastocyst, 500 microns, grade 1)	4
1406	25mg	1	1	1(blastocyst, 300 microns, grade 1)	4
9197	25mg	1	1	0	6














Mare	Dose recombinant equine FSH QID	#  follicles =35 mm at moment of hCG administration	# Ovulations	# embryo’s	Days in treatment
3137	0.25 mg	2	2	0	4
0331	0.5 mg	4	5	0	4









* No ovulation after two doses of hCG and one dose of Des, no embryo flush performed
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